From Beta to Alpha: The Evolution of Radioligand Therapies in Neuroendocrine Tumor Management
The field of oncology has seen transformative progress with the advent of radioligand therapies (RLTs), a class of precision medicine that uses radioactive isotopes to target and destroy cancer cells. Within the domain of neuroendocrine tumors (NETs), these therapies are making significant strides, moving from traditional beta-emitter radioligands to cutting-edge alpha-emitter...
0 aandelen
95 Views
0 voorbeeld